Literature DB >> 26686373

Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Hae Min Kang1,2, Hyoung Jun Koh1, Sung Chul Lee3.   

Abstract

PURPOSE: To investigate the predictive factors for recurrence of polypoidal choroidal vasculopathy (PCV).
METHODS: The medical records of 78 consecutive patients (78 eyes) with treatment-naïve PCV who responded to first-line treatment and completed at least a 3-year follow-up after the first remission were retrospectively analyzed. In this comparative cohort study, baseline characteristics were compared between the patients who had at least one recurrence (the recurrence group) and those without recurrence (the non-recurrence group) during at least 3-year follow-up periods. In addition, possible predictive factors for recurrence of PCV were investigated by using Cox regression analysis.
RESULTS: Within 3 years of the first remission, 50 eyes (64 %) showed at least one recurrence (mean 1.5; 1 to ∼2 times). There were no significant differences in the baseline characteristics between the recurrence group and the non-recurrence group. However, the largest polyp diameter was significantly different: the mean largest polyp diameter (524 ± 340 μm) was significantly larger in the recurrence group compared to that of the non-recurrence group (352 ± 173 μm; P = 0.038). Cox regression analysis showed that the largest polyp diameter at baseline significantly correlated with recurrence of PCV (B = 1.470, P = 0.015).
CONCLUSIONS: The largest polyp diameter at baseline may be predictive for PCV recurrence, as it was significantly larger in patients who had at least one recurrence.

Entities:  

Keywords:  Anti-vascular endothelial growth factor therapy; Photodynamic therapy; Polypoidal choroidal vasculopathy; Recurrence

Mesh:

Substances:

Year:  2015        PMID: 26686373     DOI: 10.1007/s00417-015-3241-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  40 in total

1.  Tomographic features of branching vascular networks in polypoidal choroidal vasculopathy.

Authors:  Taku Sato; Shoji Kishi; Goro Watanabe; Hidetaka Matsumoto; Ryo Mukai
Journal:  Retina       Date:  2007-06       Impact factor: 4.256

2.  Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh
Journal:  Am J Ophthalmol       Date:  2013-07-24       Impact factor: 5.258

3.  Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin.

Authors:  Rufino M Silva; João Figueira; M Luz Cachulo; Liliane Duarte; José R Faria de Abreu; J G Cunha-Vaz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

4.  Polypoidal choroidal vasculopathy: simultaneous indocyanine green angiography and eye-tracked spectral domain optical coherence tomography findings.

Authors:  Samira Khan; Michael Engelbert; Yutaka Imamura; K Bailey Freund
Journal:  Retina       Date:  2012-06       Impact factor: 4.256

5.  Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy.

Authors:  Akitaka Tsujikawa; Yumiko Ojima; Kenji Yamashiro; Isao Nakata; Sotaro Ooto; Hiroshi Tamura; Hideo Nakanishi; Hisako Hayashi; Atsushi Otani; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2011-03-31       Impact factor: 5.258

6.  Pigment epithelial detachment in polypoidal choroidal vasculopathy.

Authors:  Akitaka Tsujikawa; Manabu Sasahara; Atsushi Otani; Norimoto Gotoh; Takanori Kameda; Daisuke Iwama; Yuko Yodoi; Hiroshi Tamura; Michiko Mandai; Nagahisa Yoshimura
Journal:  Am J Ophthalmol       Date:  2006-09-28       Impact factor: 5.258

7.  Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy.

Authors:  R F Spaide; L A Yannuzzi; J S Slakter; J Sorenson; D A Orlach
Journal:  Retina       Date:  1995       Impact factor: 4.256

8.  Role of photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Mitsuko Yuzawa; Yoko Matsumoto; Shiho Kashiwakura; Kyoko Fujita; Ryusaburo Mori
Journal:  Jpn J Ophthalmol       Date:  2007-08-03       Impact factor: 2.447

9.  Five-year results of photodynamic therapy with and without supplementary antivascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-07       Impact factor: 3.117

10.  Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy.

Authors:  Eriko Akaza; Ryusaburo Mori; Mitsuko Yuzawa
Journal:  Retina       Date:  2008-05       Impact factor: 4.256

View more
  6 in total

1.  Submacular hemorrhage and grape-like polyp clusters: factors associated with reactivation of the lesion in polypoidal choroidal vasculopathy.

Authors:  J H Kim; Y S Chang; J W Kim; C G Kim; D W Lee
Journal:  Eye (Lond)       Date:  2017-07-14       Impact factor: 3.775

2.  One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy.

Authors:  Mio Hosokawa; Yuki Morizane; Masayuki Hirano; Shuhei Kimura; Fumiaki Kumase; Yusuke Shiode; Shinichiro Doi; Shinji Toshima; Mika Hosogi; Atsushi Fujiwara; Toshiharu Mitsuhashi; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2016-12-07       Impact factor: 2.447

3.  One-Year Outcome of Combination Therapy with Full or Reduced Photodynamic Therapy and One Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.

Authors:  Miki Sato-Akushichi; Shinji Ono; Tatsuro Taneda; Gerd Klose; Asuka Sasamori; Youngseok Song
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-15

4.  Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy.

Authors:  Yuting Peng; Xiongze Zhang; Miaoling Li; Bing Liu; Lan Mi; Chengguo Zuo; Feng Wen
Journal:  Drug Des Devel Ther       Date:  2018-02-19       Impact factor: 4.162

5.  Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy.

Authors:  Seonghee Choi; Hae Min Kang; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-27       Impact factor: 3.117

6.  Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy.

Authors:  Young-Joon Jeon; Jae-Hui Kim; Jong-Woo Kim; Chul-Gu Kim
Journal:  J Clin Med       Date:  2021-12-08       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.